News

Nerviano Medical Sciences Srl (NMS) is pleased to announce the publication of the hot-off-the-press article “Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins” published in The Journal of Organic Chemistry  (https://doi.org/10.1021/acs.joc.3c02386) .

(Click the title for the complete article)

NERVIANO and MILAN, Italy, December 14, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).

(Click the title for the complete article)

NERVIANO, IT and BOSTON, Mass, December 1, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Serena Alvino as its Chief Legal, Biotech & Transaction, effective immediately.

(Click the title for the complete article)

We are pleased to announce that Dr. Gianluca Papeo and Dr. Maurizio Pulici from NMS Srl are invited to be part of the permanent round table of the Pharmaceutical Division of the Italian Chemical Society (SCI) which gathers representative of the Italian Pharmaceutical industry and the Academic world to liaise their relationships under the patronage of the SCI.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Tiziano Lazzaretti as its new Chief Financial Officer (CFO). Tiziano brings a wealth of leadership experience in corporate strategies, finance, and governance, acquired across diverse industries, including chemicals, pharmaceuticals and biotechnology sectors.

(Click the title for the complete article)

NERVIANO, IT and BOSTON, Mass, October 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, reported today, initial results from the dose escalation parts of two Phase I-I/II studies for NMS-03305293 (NMS-293). As an oral, brain penetrant PARP-1 selective inhibitor, NMS-293 has shown strong antitumor activity and complete tumor regression in BRCA mutated preclinical models as a single agent. NMS-293 shows remarkable selectivity towards PARP-1 and efficiently inhibits cellular PARP activity resulting in selective antiproliferative responses on BRCA mutated cell lines. Furthermore, NMS-293 is synergistic and well tolerated in combination with temozolomide (TMZ) in both MGMT methylated and MGMT unmethylated glioblastoma mouse models. For the first time, clinical data is being presented during the poster session (Abstract 37568) at the AACR-NCI-EORCT 2023 Annual Meeting in Boston, Massachusetts. The poster will be available today on the NMS websites.

(Click the title for the complete article)

NMS Group- Nerviano Medical Sciences will participate to the 2023 BIO Europe partnering event, which will be held in Munich from November 6th to 8th and online from November 14th to 15th, 2023.  

(Click the title for the complete article)

NERVIANO, IT and BOSTON, Mass, October 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, with two poster presentations

(Click the title for the complete article)

La EBW è una settimana di eventi e incontri in tutta Europa per raccontare le biotecnologie nei diversi settori di applicazione ad un pubblico vasto e diversificato, sottolineando il ruolo chiave che queste tecnologie hanno nel migliorare la qualità della vita di tutti noi.

(Click the title for the complete article)